We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App





Gilead’s Antiviral Remdesivir Prevents Disease Progression in Monkeys with COVID-19

By HospiMedica International staff writers
Posted on 21 Apr 2020
Print article
Image: Gilead’s Antiviral Remdesivir Prevents Disease Progression in Monkeys with COVID-19  (Photo courtesy of Gilead Sciences)
Image: Gilead’s Antiviral Remdesivir Prevents Disease Progression in Monkeys with COVID-19 (Photo courtesy of Gilead Sciences)
A study by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases {(NIAID) Rockville, MD, USA} has found that early treatment with Gilead Sciences’ (Foster City, CA, USA) remdesivir significantly reduced clinical disease and damage to the lungs of rhesus macaques infected with SARS-CoV-2. The study was designed to follow dosing and treatment procedures used for hospitalized COVID-19 patients being administered the experimental antiviral drug in a large, multi-center, clinical trial

The study involved two groups of six rhesus macaques, with one group receiving remdesivir and the other animals being served as an untreated comparison group. The scientists infected both the groups with SARS-CoV-2 and administered an intravenous dose of remdesivir to the treatment group after 12 hours, followed by a daily intravenous booster dose for the next six days. The scientists timed the initial treatment to occur shortly before the virus reached its highest level in the animals’ lungs.

The scientists examined all animals 12 hours after the initial treatment and found the six treated animals to be in significantly better health than the untreated group, with the trend continuing over the course of the seven-day study. One of the six treated animals exhibited mild breathing difficulty, whereas all the six untreated animals showed rapid and difficult breathing. The amount of virus found in the lungs of the animals in the treatment group was significantly than those in the untreated group, and SARS-CoV-2 caused less damage to the lungs of the treated animals than the untreated animals.

The scientists believe that the data supports initiating remdesivir treatment in COVID-19 patients as early as possible to achieve maximum treatment effect, although they have noted that while remdesivir helped prevent pneumonia, it did not reduce virus shedding by the animals.

Related Links:
Gilead Sciences
National Institute of Allergy and Infectious Diseases


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
New
Diagnosis Display System
C1216W
New
Digital Radiographic System
OMNERA 300M

Print article

Channels

Critical Care

view channel
Image: Changes in immune cells can predict patient recovery following out-of-hospital cardiac arrest (Photo courtesy of Adobe Stock)

Activating T Cells Could Improve Neurological Outcomes After Cardiac Arrest

Despite advancements in cardiopulmonary resuscitation (CPR) and improved hospital access, survival rates after out-of-hospital cardiac arrest (OHCA) remain low, with only about 10% of patients surviving.... Read more

Surgical Techniques

view channel
Image: (Left) An image of a 3D-printed material implanted in vivo for 4 weeks. (Right) A photo of coral (Photo courtesy of Dr Zhidao Xia and Jesus Cobaleda)

Revolutionary Coral-Inspired Material for Bone Repair Promotes Faster Healing

Bone defects caused by fractures, tumors, and non-healing injuries are major contributors to disability worldwide. Traditionally, doctors have used either a patient’s own bone (autograft) or donor bone... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.